103.43 USD
-2.9 (-2.73%)
103.75 USD
+0.32 (+0.31%)
We assign a fundamental rating of 6 out of 10 to INCY. INCY was compared to 528 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making INCY a very profitable company, without any liquidiy or solvency issues. INCY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make INCY a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
INCY had positive earnings in the past year.
In the past year INCY had a positive cash flow from operations.
Of the past 5 years INCY 4 years were profitable.
Of the past 5 years INCY 4 years had a positive operating cash flow.
1.2 Ratios
INCY has a better Return On Assets (18.78%) than 96.78% of its industry peers.
INCY has a better Return On Equity (25.55%) than 96.97% of its industry peers.
INCY has a better Return On Invested Capital (19.88%) than 97.73% of its industry peers.
The Average Return On Invested Capital over the past 3 years for INCY is significantly below the industry average of 18.28%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROIC | 19.88% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
INCY has a Profit Margin of 24.69%. This is amongst the best in the industry. INCY outperforms 94.70% of its industry peers.
INCY's Profit Margin has declined in the last couple of years.
INCY's Operating Margin of 26.10% is amongst the best of the industry. INCY outperforms 95.83% of its industry peers.
In the last couple of years the Operating Margin of INCY has declined.
The Gross Margin of INCY (93.47%) is better than 94.51% of its industry peers.
In the last couple of years the Gross Margin of INCY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
INCY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, INCY has less shares outstanding
The number of shares outstanding for INCY has been reduced compared to 5 years ago.
Compared to 1 year ago, INCY has a worse debt to assets ratio.
2.2 Solvency
INCY has an Altman-Z score of 9.41. This indicates that INCY is financially healthy and has little risk of bankruptcy at the moment.
INCY's Altman-Z score of 9.41 is amongst the best of the industry. INCY outperforms 82.01% of its industry peers.
INCY has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
INCY has a Debt to FCF ratio of 0.03. This is amongst the best in the industry. INCY outperforms 96.40% of its industry peers.
INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of INCY (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 9.41 |
ROIC/WACC2.25
WACC8.82%
2.3 Liquidity
A Current Ratio of 3.20 indicates that INCY has no problem at all paying its short term obligations.
INCY has a Current ratio of 3.20. This is in the lower half of the industry: INCY underperforms 61.93% of its industry peers.
A Quick Ratio of 3.13 indicates that INCY has no problem at all paying its short term obligations.
INCY has a worse Quick ratio (3.13) than 60.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 575.79% over the past year.
The earnings per share for INCY have been decreasing by -14.21% on average. This is quite bad
INCY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.09%.
INCY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.46% yearly.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
The Earnings Per Share is expected to grow by 29.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, INCY will show a small growth in Revenue. The Revenue will grow by 1.31% on average per year.
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y29.11%
Revenue Next Year18.26%
Revenue Next 2Y14.47%
Revenue Next 3Y12.87%
Revenue Next 5Y1.31%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.11, which indicates a correct valuation of INCY.
Based on the Price/Earnings ratio, INCY is valued cheaply inside the industry as 95.64% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.30. INCY is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 12.85, the valuation of INCY can be described as correct.
Based on the Price/Forward Earnings ratio, INCY is valued cheaper than 96.78% of the companies in the same industry.
INCY is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.11 | ||
| Fwd PE | 12.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaply inside the industry as 95.64% of the companies are valued more expensively.
96.02% of the companies in the same industry are more expensive than INCY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.96 | ||
| EV/EBITDA | 12.98 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INCY has a very decent profitability rating, which may justify a higher PE ratio.
INCY's earnings are expected to grow with 91.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y146.91%
EPS Next 3Y91%
5. Dividend
5.1 Amount
INCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
103.43
-2.9 (-2.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.27%
Inst Owner Change0.23%
Ins Owners0.96%
Ins Owner Change-10.13%
Market Cap20.31B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts75.63
Price Target101.7 (-1.67%)
Short Float %5.6%
Short Ratio4.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)5.65%
PT rev (3m)18.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.9%
EPS NY rev (1m)0%
EPS NY rev (3m)10.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.11 | ||
| Fwd PE | 12.85 | ||
| P/S | 4.22 | ||
| P/FCF | 16.96 | ||
| P/OCF | 16.23 | ||
| P/B | 4.37 | ||
| P/tB | 4.64 | ||
| EV/EBITDA | 12.98 |
EPS(TTM)6.42
EY6.21%
EPS(NY)8.05
Fwd EY7.78%
FCF(TTM)6.1
FCFY5.9%
OCF(TTM)6.37
OCFY6.16%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.04
PEG (5Y)N/A
Graham Number58.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROCE | 25.17% | ||
| ROIC | 19.88% | ||
| ROICexc | 48.14% | ||
| ROICexgc | 55.55% | ||
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% | ||
| FCFM | 24.87% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 59.08% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.81% | ||
| Profit Quality | 100.71% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 9.41 |
F-Score7
WACC8.82%
ROIC/WACC2.25
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y29.11%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18.26%
Revenue Next 2Y14.47%
Revenue Next 3Y12.87%
Revenue Next 5Y1.31%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.61%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 6 / 10 to INCY.
What is the valuation status of INCYTE CORP (INCY) stock?
ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
How financially healthy is INCYTE CORP?
The financial health rating of INCYTE CORP (INCY) is 7 / 10.
Can you provide the expected EPS growth for INCY stock?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 428.71% in the next year.